SCHEMBL4232176

SCHEMBL4232176

COc1cc(NC(=O)NC(C)C)ccc1Oc1ccc(N)cc1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 1/20 0.46
MAPT P10636 4/20 0.46
KMT2A Q03164 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
MEN1 O00255 2/20 0.46
ALDH1A1 P00352 2/20 0.46
TP53 P04637 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
LMNA P02545 2/20 0.44
MCHR1 Q99705 1/20 0.44
MAPK1 P28482 1/20 0.43
PDGFRA P16234 1/20 0.43
KDR P35968 1/20 0.43
THRB P10828 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5183338 0.93 MAPK1 (0.46) MAPTKMT2ASMN1; SMN2MEN1TP53
SCHEMBL4228811 0.87 PKM (0.60) FPR2MAPTKMT2ASMN1; SMN2MEN1
Ammonia Solution, Strong SCHEMBL4235457 0.86 PKM (0.58) FPR2MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL13699200 0.86 MAPK1 (0.42) MAPTKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL4798423 0.86 PKM (0.44) FPR2MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL5181890 0.85 PNLIP (0.55) MAPT
SCHEMBL4684325 0.84 MAPK1 (0.43) MAPTALDH1A1RAB9AMAPK1POLB
SCHEMBL5180344 0.83 MMP2 (0.42) FPR2MAPTALDH1A1RAB9AMAPK1
SCHEMBL4687674 0.83 RAB9A (0.51) MAPTKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL5184216 0.83 KMT2A (0.46) MAPTKMT2ASMN1; SMN2MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R FPR2 105/4885MAPT 1398/4885KMT2A 3436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.